alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
FOR IMMEDIATE RELEASE Contact: Angelia Rorison

February 1, 2024 publicaffairs@usccr.gov

Public Briefing

Civil Rights Implications of the Federal Use of Facial

Recognition Technology

March 8, 2024 | Washington, D.C.

The U.S. Commission on Civil Rights will hold a briefing on, Friday, March 8, 2024, on the civil

rights implications of Facial Recognition Technology (FRT). This investigation will analyze how

FRT is developed, how it is being utilized by federal agencies, emerging civil rights concerns, and

safeguards the federal government is implementing to mitigate potential civil rights issues.

Specifically, the Commission will review the utilization of FRT technology by three cabinet

agencies: U.S. Department of Justice (DOJ), U.S. Department of Homeland Security (DHS), and

U.S. Department of Housing and Urban Development (HUD).

At this public briefing, the Commission will hear from subject matter experts such as government

officials, academics, researchers, software developers, and legal experts. The Commission will

accept written materials from the public for consideration as we prepare our report; submit to

frt@usccr.gov no later than April 8, 2024.

DATE:

Friday, March 8, 2024, 10 am – 5 pm ET*

LOCATION:

U.S. Commission on Civil Rights

1331 Pennsylvania Ave., NW, Suite 1150

Washington, DC 20425 (National Place Building F Street Entrance)

***The briefing will also be live-streamed on the Commission’s YouTube page, virtual

attendance is encouraged due to limited space.***

Open Comment Session (public testimony): Written comments submitted to frt@usccr.gov by

April 8, 2024.

Stay abreast of updates at www.usccr.gov and on X and Facebook.

*Schedule subject to change

###

The U.S. Commission on Civil Rights, established by the Civil Rights Act of 1957, is the only independent, bipartisan

agency charged with advising the President and Congress on civil rights and reporting annually on federal civil rights

enforcement. Our 56 state Advisory Committees offer a broad perspective on civil rights concerns at state and local

levels. The Commission: in our 7th decade, a continuing legacy of influence in civil rights. For information about the

Commission, please visit www.usccr.gov and on Twitter and Facebook.
CACHE LA POUDRE RIVER AT FORT COLLINS, COLatitude: 40.589Longitude: -105.07Elevation: 4940

CACHE LA POUDRE RIVER AT FORT COLLINS, CO

Courtesy NRCS - Go to Hourglass Lake Site Page...



Hourglass Lake

Courtesy NRCS - Go to Long Draw Resv Site Page...



Long Draw Resv

Courtesy NRCS - Go to Black Mountain Site Page...



Black Mountain

Courtesy NRCS - Go to Deadman Hill Site Page...



Deadman Hill

Courtesy NRCS - Go to Joe Wright Site Page...



Joe Wright

Courtesy NRCS - Go to Lake Irene Site Page...



Lake Irene

Courtesy NRCS - Go to Phantom Valley Site Page...



Phantom Valley

Courtesy NRCS - Go to Willow Park Site Page...



Willow Park
# C_2009111EN.01000401.xml

| 15.5.2009 | EN | Official Journal of the European Union | C 111/4 |
| --- | --- | --- | --- |

15.5.2009

EN

Official Journal of the European Union

C 111/4

---

COUNCIL ACT

COUNCIL ACT

of 6 April 2009

appointing the Director of Europol

2009/C 111/02

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Convention on the establishment of a European Police Office (Europol Convention) (1), and in particular Article 29(1) thereof,

1

Acting as the authority vested with the power to appoint the Director of Europol,

Having regard to the opinion of the Management Board,

Whereas:

| (1) | Due to the expiry of the term of office of the Director of Europol appointed by Council Act of 28 February 2005 (2), it is necessary to appoint a Director. |
| --- | --- |

(1)

Due to the expiry of the term of office of the Director of Europol appointed by Council Act of 28 February 2005 (2), it is necessary to appoint a Director.

2

| (2) | The Staff Regulations applicable to Europol employees (3), and in particular their Appendix 8, establish special provisions on the procedure for the selection of the Director or a Deputy Director of Europol. |
| --- | --- |

(2)

The Staff Regulations applicable to Europol employees (3), and in particular their Appendix 8, establish special provisions on the procedure for the selection of the Director or a Deputy Director of Europol.

3

| (3) | The Management Board presented the Council with a short-list ranking the suitable applicants for appointment, together with the full file of each of those applicants, as well as the full list of the applicants. |
| --- | --- |

(3)

The Management Board presented the Council with a short-list ranking the suitable applicants for appointment, together with the full file of each of those applicants, as well as the full list of the applicants.

| (4) | On the basis of all relevant information provided by the Management Board, the Council wishes to appoint the applicant who, according to the Council, meets all the requirements of the vacant position of Director, |
| --- | --- |

(4)

On the basis of all relevant information provided by the Management Board, the Council wishes to appoint the applicant who, according to the Council, meets all the requirements of the vacant position of Director,

HAS DECIDED AS FOLLOWS:

Article 1

Mr Robert WAINWRIGHT is hereby appointed as Director of Europol from 16 April 2009 to 15 April 2013.

Article 2

This Act shall take effect on the day of its adoption.

It shall be published in the Official Journal of the European Union.

Official Journal of the European Union

Done at Luxembourg, 6 April 2009.

For the Council

The President

J. POSPÍŠIL

---

(1)  OJ C 316 of 27.11.1995, p. 2.

1

(2)  OJ C 60, 10.3.2005, p. 2.

2

(3)  See Council Act of 3 December 1998 laying down the staff regulations applicable to Europol employees (OJ C 26, 30.1.1999, p. 23) as amended by Council Act of 19 December 2002 (OJ C 24 of 31.1.2003, p. 1).

3

---
EXHIBIT
32.1




Certification
of Chief Executive Officer and  Chief Financial Officer


pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002


regarding
Quarterly Report on Form 10-Q for the quarter ended March 31,
2008





Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of
section 1350, chapter 63 of title 18, United States Code), the undersigned
officer of a Texas corporation (the “Company”), does hereby certify
that:





1.  The
Company's Quarterly Report on Form 10-Q for the fiscal period ended March 31,
2008, (the Form 10Q-SB) fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934, as amended; and





2.  Information
contained in the Form 10-Q fairly presents, in all material respects, the
financial condition and results of operations of the Company.














Date:           June 4,
2008                                                      By:           /s/ Steven L.
Sample


Steven L.
Sample


Chief
Executive Officer and Principal Financial Officer
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 9
<MULTIPLIER> 1

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          JUN-30-1999
<PERIOD-END>                               JUN-30-1999
<CASH>                                       1,111,855
<INT-BEARING-DEPOSITS>                       6,350,923
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                          0
<INVESTMENTS-CARRYING>                         150,275
<INVESTMENTS-MARKET>                           150,000
<LOANS>                                    134,459,151
<ALLOWANCE>                                    926,546
<TOTAL-ASSETS>                             159,418,410
<DEPOSITS>                                 101,423,598
<SHORT-TERM>                                 9,300,000
<LIABILITIES-OTHER>                          1,481,920
<LONG-TERM>                                 20,150,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        10,319
<OTHER-SE>                                  16,947,062
<TOTAL-LIABILITIES-AND-EQUITY>             150,405,903
<INTEREST-LOAN>                             11,559,524
<INTEREST-INVEST>                                5,922
<INTEREST-OTHER>                               352,341
<INTEREST-TOTAL>                            11,917,787
<INTEREST-DEPOSIT>                           4,598,959
<INTEREST-EXPENSE>                           6,484,467
<INTEREST-INCOME-NET>                        5,433,320
<LOAN-LOSSES>                                  298,020
<SECURITIES-GAINS>                                   0
<EXPENSE-OTHER>                              1,022,291
<INCOME-PRETAX>                              1,759,785
<INCOME-PRE-EXTRAORDINARY>                   1,109,581
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,109,581
<EPS-BASIC>                                       1.26
<EPS-DILUTED>                                     1.26
<YIELD-ACTUAL>                                    7.84
<LOANS-NON>                                    553,902
<LOANS-PAST>                                         0
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                               669,000
<CHARGE-OFFS>                                   82,164
<RECOVERIES>                                    42,233
<ALLOWANCE-CLOSE>                              926,546
<ALLOWANCE-DOMESTIC>                           926,546
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0



</TABLE>
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JUN-30-2001
<PERIOD-START>                             JUL-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                         131,455
<SECURITIES>                                    17,607
<RECEIVABLES>                                   18,318
<ALLOWANCES>                                     3,837
<INVENTORY>                                     11,852
<CURRENT-ASSETS>                               176,705
<PP&E>                                          16,648
<DEPRECIATION>                                   8,108
<TOTAL-ASSETS>                                 189,778
<CURRENT-LIABILITIES>                           16,699
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       131,692
<OTHER-SE>                                      40,047
<TOTAL-LIABILITY-AND-EQUITY>                   189,778
<SALES>                                         33,360
<TOTAL-REVENUES>                                33,360
<CGS>                                           19,050
<TOTAL-COSTS>                                   25,622
<OTHER-EXPENSES>                                   225
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                  9,736
<INCOME-TAX>                                     3,700
<INCOME-CONTINUING>                              6,036
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     6,036
<EPS-BASIC>                                       0.24
<EPS-DILUTED>                                     0.22


</TABLE>
#### The People of the State of New York, Respondent, v Anibal Crespo, Appellant.

Judgment, Supreme Court, Bronx County (Richard Price, J.), rendered on July 30, 1985, unanimously affirmed.

Application by appellant’s counsel to withdraw as counsel is granted. *(See, Anders v California,*386 US 738; *People v Saunders,*52 AD2d 833.) We have reviewed this record and agree with appellant’s assigned counsel that there are no nonfrivolous points which could be raised on this appeal. Concur—Ross, J. P., Asch, Rosenberger, Ellerin and Wallach, JJ.
### TEXAS COURT OF APPEALS, THIRD DISTRICT, AT AUSTIN

JUDGMENT RENDERED JU NE 10, 2016

NO. 03

- 15

- 00410

- CR

Edgar Sangillo, Appellant

v.

The State of Texas, Appellee

APPEAL FROM 299TH DISTRICT COURT OF TRAVIS COUNTY

BEFORE CH I EF JUSTICE ROSE, JUS TICES PURYEAR AND PEMBERTO N

AFFIRMED

-- OPINION BY JUSTICE PURYEAR

This is an appeal from the judgment revoking community supervision entered by the trial

court. Having reviewed the record and the parties’ arguments, th e Court holds that there was

no reversible error in the trial court’s judgment . Therefore, the Court affirms the trial court’s

judgment revoking community supervision

. Because appellant is indigent and unable to pay

costs, no adjudication of costs is made.

### TEXAS COURT OF APPEALS, THIRD DISTRICT, AT AUSTIN

JUDGMENT RENDERED JU NE 10, 2016

NO. 03

- 15

- 00411

- CR

Edgar Sangillo, Appellant

v.

The State of Texas, Appellee

APPEAL FROM 299TH DISTRICT COURT OF TRAVIS COUNTY

BEFORE CHIEF JUSTICE ROSE, JUSTICES PURYEAR AND PEMBERTO N
MODIF IED AND, AS MODIFIED, AFFIRMED

-- OPINION BY JUSTICE PURYEAR

This is an appeal from the judgment revoking community supervision entered by the tr i a l court.

Having reviewed the record and the parties’ arguments, the Court ho lds that there was no error in

the court’s judgment requiring reversal . Therefore, the Court affirms the trial court’s judgment.

H owever, there was error in the judgment that requires correction. Therefore, the Court modifies

the trial court’s judgment to delete the language st ating that appellant “FAILED TO

COMPLETE 250 HOURS OF COMMUNITY SERVICE RESTITUTION

, ” and to reflect that

Sangillo was convicted under subsection 550. 021(c)(2) of the Transportation Code. The

judgment, as modified, is affirmed

. Because appellant is indig ent and unable to pay costs, no

adjudication of costs is made.
----

|   | 1. | The      Quarterly Report fully complies with the requirements of Section 13(a) or      15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d));      and |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | The      information contained in the Quarterly Report fairly presents, in all      material respects, the financial condition and results of operations of      the Company. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |    /s/  Daniel      R. Baty |
|--------|------------------------------------------------------|
|   | Daniel      R. Baty                                  |
|   | Co-Chief      Executive Officer                      |
|   | August      6, 2009                                  |

----
EX-10.4





 Exhibit 10.4 

AMENDMENT NO. 2 TO PROCESS DEVELOPMENT AGREEMENT 

This AMENDMENT NO. 2 TO PROCESS DEVELOPMENT AGREEMENT (this “Amendment”) is effective as of this 3rd day of
June, 2021 (the “Amendment Effective Date”), and is entered into by and between Tyligand Bioscience (Shanghai) Limited, having its registered office at 3728 Jinke Road, Building 1 West Wing, ZhangJiang Hitech Park, Shanghai,
China (“Tyligand”) and Context Therapeutics LLC, a Delaware limited liability company having its registered office at 3675 Market Street, Suite 200, Philadelphia, PA 19104 (“Context”). Tyligand and
Context are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 

RECITALS 

WHEREAS, Tyligand and Context entered into that certain Process Development Agreement, effective as of the 6th of March 2020, as amended by Amendment No. 1 effective as of the 6th of March 2021 (as amended, the “Development
Agreement”), which outlines the rights and obligations of Tyligand and Context with respect to the conduct of certain services to be performed by Tyligand; 

WHEREAS, the Parties wish to enter into this Amendment in order to amend certain provisions therein in accordance with the terms and
conditions set forth herein; 
 NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows: 
 1. Defined Terms. All capitalized
terms used herein shall have the meaning ascribed to each of them as defined herein and, if not defined herein, shall have the meaning ascribed to each of them in the Development Agreement. 

2. Amendment to Term of Development Agreement. Entered into as of the Amendment Effective Date, the reference to “fifteen
(15) months” in Section 10.1 of the Development Agreement is hereby be amended and restated to instead be “seventeen (17) months”. 

3. Entire Agreement. Each Party acknowledges that this Amendment, together with the Development Agreement, constitutes the
entire agreement of the Parties with respect to the subject matter hereof. 
 4. Full Force and Effect. Except as expressly
amended hereby, all of the other terms and conditions of the Development Agreement shall remain unchanged and in full force and effect in accordance with their original terms. 

5. Authority. Each Party hereby represents and warrants that is has full power and authority to enter into this Amendment. 

[Signature page follows] 

  
 1 













 IN WITNESS WHEREOF, the Parties have each caused a duly authorized representative to
execute this Amendment as of the Amendment Effective Date. 
  

			
	CONTEXT:	  	TYLIGAND:
		
	Context Therapeutics LLC	  	Tyligand Bioscience (Shanghai) Limited
		
	 By: /s/ Alex
Levit                                    
	  	By: /s/ Tony Y. Zhang                            
		
	 Name: Alex Levit
	  	Name: Tony Y. Zhang
		
	 Title: Chief Legal Officer
	  	Title: CEO


  
 2
xml version="1.0" encoding="UTF-8"?


C\_2021413EN.01001401.xml


| | | | |
| --- | --- | --- | --- |
| 12.10.2021 | EN | Official Journal of the European Union | C 413/14 |

---

Prior notification of a concentration

(Case M.10482 – CVC/Carlyle/CFGI Eagle Parent)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 413/12)

1.

On 27 September 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [(1)](#ntr1-C_2021413EN.01001401-E0001).

This notification concerns the following undertakings:

| | |
| --- | --- |
| — | CVC Capital Partners SICAV-FIS S.A. (‘CVC’, Luxembourg), |

| | |
| --- | --- |
| — | The Carlyle Group, Inc. (‘Carlyle’, USA), |

| | |
| --- | --- |
| — | CFGI Eagle Parent, LLC (‘CFGI’, USA), currently controlled by Carlyle. |

CVC and Carlyle acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of CFGI.

The concentration is accomplished by way of purchase of shares.

2.

The business activities of the undertakings concerned are:

| | |
| --- | --- |
| — | for CVC: manager of investment funds and platforms holding interests in a number of companies in various industries primarily in Europe, the USA and the Asia-Pacific region, |

| | |
| --- | --- |
| — | for Carlyle: global alternative asset manager, |

| | |
| --- | --- |
| — | for CFGI: financial consulting firm active in the USA focused on offering technical accounting and finance advisory services. |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 [(2)](#ntr2-C_2021413EN.01001401-E0002) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10482 – CVC/Carlyle/CFGI Eagle Parent

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| |
| --- |
| European Commission |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

---

[(1)](#ntc1-C_2021413EN.01001401-E0001)  [OJ L 24, 29.1.2004, p. 1](http://publications.europa.eu/resource/oj/JOL_2004_024_R_TOC) (the ‘Merger Regulation’).

[(2)](#ntc2-C_2021413EN.01001401-E0002)  [OJ C 366, 14.12.2013, p. 5](http://publications.europa.eu/resource/oj/JOC_2013_366_R_TOC).

---
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE GELTEX
PHARMACEUTICALS, INC. FORM 10-Q AND THE NOTES THERETO FOR THE QUARTERLY PERIOD
ENDED MARCH 31, 1999 AND IS QUALIFITED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               MAR-31-1999
<EXCHANGE-RATE>                                      1
<CASH>                                      23,079,762
<SECURITIES>                                70,236,794
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                    776,954
<CURRENT-ASSETS>                           107,908,044
<PP&E>                                      11,782,000
<DEPRECIATION>                               3,834,484
<TOTAL-ASSETS>                             123,988,363
<CURRENT-LIABILITIES>                        6,451,757
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       168,447
<OTHER-SE>                                 112,161,979
<TOTAL-LIABILITY-AND-EQUITY>               123,988,363
<SALES>                                              0
<TOTAL-REVENUES>                             3,634,583
<CGS>                                                0
<TOTAL-COSTS>                               12,519,743
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             134,404
<INCOME-PRETAX>                            (7,737,060)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (7,737,060)
<EPS-PRIMARY>                                    (.46)
<EPS-DILUTED>                                    (.46)
        

</TABLE>